Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.85 CAD | +22.84% | +20.76% | +578.57% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
Sales 2024 * | - | Sales 2025 * | 438K 321K | Capitalization | 213M 156M |
---|---|---|---|---|---|
Net income 2024 * | -15M -11M | Net income 2025 * | -19M -13.93M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 487 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-11
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.81% |
Latest transcript on Medicenna Therapeutics Corp.
1 day | +22.84% | ||
1 week | +20.76% | ||
1 month | +22.84% | ||
3 months | +154.46% | ||
6 months | +481.63% | ||
Current year | +578.57% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 11-09-30 | |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
David Hyman
DFI | Director of Finance/CFO | - | Feb. 13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 19-09-23 |
Albert Beraldo
BRD | Director/Board Member | - | 16-11-21 |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.85 | +22.84% | 213,489 |
24-05-30 | 2.32 | +2.20% | 106,973 |
24-05-29 | 2.27 | -1.30% | 78,425 |
24-05-28 | 2.3 | -5.74% | 43,298 |
24-05-27 | 2.44 | +3.39% | 28,726 |
Delayed Quote Toronto S.E., May 31, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+578.57% | 156M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- MDNA Stock